OQR200 is directed against HER2/neu over-expressing breast cancer and induces strong polyclonal humoral (IgG) and cellular (CD4 and CD8) immune responses, superior to trastuzumab, pertuzumab or passive checkpoint inhibitors. Both lead candidates, which have achieved in vivo Proof of Concept in non-human primates, as well as the S-TIR™ technology platform are now available for out-licensing.

Cancer immunotherapy
Active therapy (protein/peptide based)
Checkpoint control
No side effects
Activation of all 4 naturally available killing mechanisms of the immune system
Multiple cancer targets

Model OQR300 -Cells